V–433 [Amended]

From Bridgeport, CT; INT Bridgeport 324° and Pawling, NY, 160° radials; Pawling; INT Pawling 304° and Rockdale, NY, 116° radials; Rockdale; INT Rockdale 325° and Syracuse, NY, 100° radials; to Syracuse.

* * * * *

V–483 [Amended]

From Syracuse, NY; Rochester, NY; INT Syracuse 283° and Rochester 064° radials; Rochester.

* * * * *

V–499 [Removed]

* * * * *

Issued in Washington, DC, on August 23, 2022.

Scott M. Rosenbloom,

Manager, Airspace Rules and Regulations.

[FR Doc. 2022–18484 Filed 8–26–22; 8:45 am]

BILLING CODE 4910–13–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[Docket No. DEA824]

Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I; Withdrawal of Proposed Rule

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Withdrawal of proposed rule.

SUMMARY: The Drug Enforcement Administration (DEA) is withdrawing a proposed rule that was published in the **Federal Register** on April 11, 2022, which proposed to place two phenethylamine hallucinogens in schedule I of the Controlled Substances Act. DEA is withdrawing the proposed rule, terminating all proceedings related thereto, and will be publishing a new proposed rule using an amended procedure.

DATES: The proposed rule that was published in the **Federal Register** on April 11, 2022 (87 FR 21069), is withdrawn as of August 25, 2022, and all proceedings related thereto are terminated.

FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Chief, Drug and Chemical Evaluation Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (571) 362–3249.

SUPPLEMENTARY INFORMATION: On April 11, 2022, the Drug Enforcement Administration (DEA) published a Notice of Proposed Rulemaking (NPRM) in the **Federal Register** (87 FR 21069) to place two phenethylamine hallucinogens—specifically, 2,5-dimethoxy-4-iodoamphetamine (DOI), and 2,5-dimethoxy-4-chloroamphetamine (DOC)—in schedule I of the Controlled Substances Act (CSA) (21 U.S.C. 801, *et seq.*).

DEA has determined that it is appropriate to withdraw the proposed rule published in the **Federal Register** on April 11, 2022 (87 FR 21069), and to terminate all proceedings related thereto. DEA is planning to publish a new proposed rule with an amended procedure.

Signing Authority

This document of the Drug Enforcement Administration was signed on August 25, 2022, by Administrator Anne Milgram. That document with the original signature and date is maintained by DEA. For administrative purposes only, and in compliance with requirements of the Office of the Federal Register, the undersigned DEA Federal Register Liaison Officer has been authorized to sign and submit the document in electronic format for publication, as an official document of DEA. This administrative process in no way alters the legal effect of this document upon publication in the **Federal Register**.

Scott Brinks,

Federal Register Liaison Officer, Drug Enforcement Administration.

[FR Doc. 2022–18729 Filed 8–26–22; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Part 493

[CMS–3326–N]

RIN 0938–AT47

Clinical Laboratory Improvement Amendments of 1988 (CLIA) Fees; Histocompatibility, Personnel, and Alternative Sanctions for Certificate of Waiver Laboratories; Extension of Comment Period

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS; Centers for Disease Control and Prevention (CDC), HHS.

ACTION: Proposed rule; extension of comment period.

SUMMARY: The Centers for Medicare & Medicaid Services (CMS) and the Centers for Disease Control and Prevention (CDC) within the Department of Health and Human Services (HHS) announce the extension of the comment period for the proposed rule entitled ''Clinical Laboratory Improvement Amendments of 1988 (CLIA) Fees; Histocompatibility, Personnel, and Alternative Sanctions for Certificate of Waiver Laboratories.''

DATES: The comment period for the proposed rule published July 26, 2022 (87 FR 44896), is extended through September 26, 2022.

ADDRESSES: In commenting, please refer to file code CMS–3326–P.

Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed):

1. *Electronically.* You may submit electronic comments on this regulation to *https://www.regulations.gov.* Follow the ''Submit a comment'' instructions.

2. *By regular mail.* You may mail written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3326–P, P.O. Box 8016, Baltimore, MD 21244–8016.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. *By express or overnight mail.* You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–3326–P, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850.

FOR FURTHER INFORMATION CONTACT: Sarah Bennett, CMS, (410) 786–3531, Serafina Brea, CMS, (410) 786–3531, or Heather Stang, CDC, 404–498–2769.

SUPPLEMENTARY INFORMATION: In the ''Clinical Laboratory Improvement Amendments of 1988 (CLIA) Fees; Histocompatibility, Personnel, and Alternative Sanctions for Certificate of Waiver Laboratories'' proposed rule that appeared in the July 26, 2022 **Federal Register** (87 FR 44896), we solicited public comments on proposed changes to CLIA fees, histocompatibility and personnel requirements, and alternative sanctions for Certificate of Waiver laboratories.

In response to requests we received from several laboratory professional organizations, we are extending the comment period an additional 30 days. This extension will maximize the opportunity for the public to provide

meaningful input to CMS and CDC) for an additional 30 days.

Dated: August 24, 2022.

Xavier Becerra,

Secretary, Department of Health and Human Services.

[FR Doc. 2022–18558 Filed 8–24–22; 4:15 pm]

BILLING CODE 4120–01–P

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

49 CFR Parts 191, 192, and 195

[Docket No. PHMSA–2020–0013]

RIN 2137–AF48

Pipeline Safety: Periodic Standards Update II

AGENCY: Pipeline and Hazardous Materials Safety Administration (PHMSA), Department of Transportation (DOT).

ACTION: Notice of proposed rulemaking.

SUMMARY: PHMSA incorporates more than 80 voluntary, consensus, industry technical standards by reference within the Federal pipeline safety regulations (PSRs). This notice of proposed rulemaking (NPRM) proposes amendments that would incorporate by reference all or parts of updated editions of some of those standards. This NPRM also proposes non-substantive edits and clarifications to certain other provisions of the PSRs.

DATES: Members of the public who are interested in submitting comments on this NPRM must do so by October 28, 2022.

ADDRESSES: You may submit comments, identified by Docket No. PHMSA–2020–0013, by any of the following methods:

- *E-Gov Web: https://www.regulations.gov.* This site allows the public to enter comments on any **Federal Register** notice issued by any agency. Follow the online instructions for submitting comments.
- *Mail:* Docket Management System, U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building: Room W12–140, Washington, DC 20590–0001.
- *Hand Delivery:* DOT Docket Management System, U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building: Room W12–140, Washington, DC 20590–0001, between 9:00 a.m. and 5:00 p.m. ET, Monday through Friday, except Federal holidays.
- *Instructions:* Identify Docket No. PHMSA–2020–0013 at the beginning of your comments. If you submit your comments by mail, submit two copies. If you would like confirmation that PHMSA received your comments, please include a self-addressed stamped postcard. Internet users may submit comments at *https://www.regulations.gov.*
- *Note:* All comments received are posted without edits to *https://www.regulations.gov,* including any personal information provided. Please see the Privacy Act heading for more information.
- *Privacy Act:* In accordance with 5 United States Code (U.S.C.) 553(c), the DOT solicits comments from the public to better inform its rulemaking process. The DOT posts these comments without edit, including any personal information the commenter provides, to *https://www.regulations.gov,* as described in the system of records notice (DOT/ALL–14 FDMS), which can be reviewed at *https://www.dot.gov/privacy.*
- *Confidential Business Information:* Confidential Business Information (CBI) is commercial or financial information that is both customarily and actually treated as private by its owner. Under the Freedom of Information Act (5 U.S.C. 552), CBI is exempt from public disclosure. If your comments in response to this notice contain commercial or financial information that is customarily treated as private, that you actually treat as private, and that is relevant or responsive to this notice, it is important that you clearly designate the submitted comments as CBI. Pursuant to 49 Code of Federal Regulations (CFR) 190.343, you may ask PHMSA to provide confidential treatment to information you give to the agency by taking the following steps: (1) mark each page of the original document submission containing CBI as ''Confidential;'' (2) send PHMSA a copy of the original document with the CBI deleted along with the original, unaltered document; and (3) explain why the information you are submitting is CBI. Submissions containing CBI should be sent to Tewabe Asebe, 1200 New Jersey Avenue SE, DOT: PHMSA—PHP–30, Washington, DC 20590–0001. Any commentary PHMSA receives that is not specifically designated as CBI will be placed in the public docket.
- *Docket:* For access to the docket or to read background documents or comments, go to *https://www.regulations.gov* and follow the online instructions to access the docket. Alternatively, you may review the documents in person at the street address listed above.

FOR FURTHER INFORMATION CONTACT:

Technical Information: Rod Seeley by phone at (713) 272–2852 or via email at *Rodrick.M.Seeley@dot.gov.*

Regulatory Information: Tewabe Asebe by phone at (202) 365–0226 or via email at *Tewabe.Asebe@dot.gov.*

SUPPLEMENTARY INFORMATION:

I. Introduction

This NPRM proposes the incorporation by reference of 28 updated, voluntary, consensus industry technical standards within the PSRs (49 CFR parts 190–199). These updated standards would generally, if adopted, maintain or improve public safety and environmental protection, prevent regulatory confusion and reduce compliance burdens on stakeholders, and satisfy a mandate in the National Technology Transfer and Advancement Act of 1995 (NTTAA) (15 U.S.C. 272 (note)), that directs Federal agencies to, ''when practical and consistent with applicable laws, use technical standards developed by voluntary consensus standard bodies instead of government-developed technical standards.'' PHMSA incorporates more than 80 consensus standards by reference into the PSRs; however, many standards become outdated over time as new editions become available. By updating these standards, PHMSA will ensure better alignment of the PSRs with the latest innovations in operational practices, testing, and technological advancements; enhance compliance by avoiding conflict between different versions of the same technical standards; and facilitate safety-focused allocation of resources by pipeline operators. Therefore, PHMSA expects that the updated standards in this rule will enhance the PSRs' protection of public safety and the environment—including avoidance of greenhouse gas emissions in the form of methane releases from natural gas pipelines—and will be technically feasible, reasonable, cost-effective, and practicable in light of